KEGG   DRUG: Idecabtagene vicleucel
Entry
D11556                      Drug                                   
Name
Idecabtagene vicleucel (USAN);
Abecma (TN)
Product
ABECMA (Celgene Corporation)
Remark
ATC code: L01XL07
Product: D11556<US>
Efficacy
Antineoplastic, Anti-BCMA CAR-T cell
  Disease
Multiple myeloma [DS:H00010]
  Type
Cellular therapy product, CAR-T cell therapy
Target
TNFRSF17 (BCMA, CD269) [HSA:608] [KO:K05153]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04672  Intestinal immune network for IgA production
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XL Antineoplastic cell and gene therapy
     L01XL07 Idecabtagene vicleucel
      D11556  Idecabtagene vicleucel (USAN) <US>
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Tumor necrosis factor receptors
    TNFRSF17 (BCMA, CD269)
     D11556  Idecabtagene vicleucel (USAN) <US>
New drug approvals in the USA [br08319.html]
 Cellular and gene therapy products
  D11556
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11556
 Cellular and gene therapy products
  D11556
New drug approvals in Japan [br08318.html]
 Cellular and gene therapy products
  D11556
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11556
Other DBs
PubChem: 384585532
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system